Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights

Business Wire May 6, 2021

Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021

Business Wire April 28, 2021

Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 15, 2021

Aurinia Presents Data Demonstrating LUPKYNIS(TM) (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings

Business Wire April 8, 2021

Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS(TM) (voclosporin) in Latest ICER Draft Evidence Report

Business Wire March 15, 2021

Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences

Business Wire March 2, 2021

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights

Business Wire February 24, 2021

Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Business Wire February 18, 2021

Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2020 Financial Results on February 24, 2021

Business Wire February 17, 2021

FDA Approves Aurinia Pharmaceuticals' LUPKYNIS(TM) (voclosporin) for Adult Patients with Active Lupus Nephritis

Business Wire January 22, 2021

Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences

Business Wire January 8, 2021

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

Business Wire December 17, 2020

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Business Wire December 15, 2020

Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Business Wire December 2, 2020

Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 20, 2020

Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference

Business Wire November 12, 2020

Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights

Business Wire November 10, 2020

Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020

Business Wire November 9, 2020

Aurinia Announces Outcome of AUDREY(TM) Clinical Trial in Dry Eye Syndrome

Business Wire November 2, 2020

Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19

Business Wire October 27, 2020